FDA Approves Illumina's TruSight Oncology Comprehensive Assay, Now Offered by PreCheck Health Services as "SolidTumorCheck+" -- A Breakthrough in Precision OncologyPRNewsWire • 09/09/24
Results of GRAIL's Galleri® Multi-Cancer Early Detection Blood Test in Prostate Cancer Published in JCO Precision OncologyPRNewsWire • 08/29/24
FDA approves Illumina cancer biomarker test with two companion diagnostics to rapidly match patients to targeted therapiesPRNewsWire • 08/27/24
Is the Options Market Predicting a Spike in Illumina (ILMN) Stock?Zacks Investment Research • 08/26/24
Illumina expects full-year sales from core segment to decline on biotech funding crunchReuters • 08/06/24
Stay Ahead of the Game With Illumina (ILMN) Q2 Earnings: Wall Street's Insights on Key MetricsZacks Investment Research • 08/01/24
Illumina (ILMN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research • 07/30/24